ALPS Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

ALPS Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,445	Closed	-$257K	–	973
2021 Q2	$257K	Buy	+1,445	New	+$250K	﹤0.01%	884

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

ALPS Advisors's JAZZ Position: Q3 2021 in Review

ALPS Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2021, closing a stake of 1,445 shares — an estimated $257K sold.

ALPS Advisors first reported a position in JAZZ in Q2 2021 and held it in 1 quarter. The position peaked at $257K in Q2 2021. 455 funds tracked by Wall St. Rank hold JAZZ as of Q3 2021.

ALPS Advisors reported no remaining Jazz Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
ALPS Advisors sold 1,445 Jazz Pharmaceuticals shares in Q3 2021, an estimated $257K.
ALPS Advisors first reported a position in Jazz Pharmaceuticals in Q2 2021 and held it in 1 quarter.
ALPS Advisors's Jazz Pharmaceuticals position peaked at $257K in Q2 2021.
455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2021.

Based on ALPS Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.